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Abstract
Background: There are approximately 3 million people aged 50 and older in sub-Saharan Africa who are HIV-positive.
Despite this, little is known about the characteristics of older adults who are on treatment and their treatment outcomes.
Methods: A retrospective cohort analysis was performed using routinely collected data with Malawi Ministry of Health
monitoring tools from facilities providing antiretroviral therapy services in Zomba district. Patients aged 25 years and older
initiated on treatment from July 2005 to June 2010 were included. Differences in survival, by age group, were determined
using Kaplan–Meier survival plots and Cox proportional hazards regression models.
Results: There were 10,888 patients aged 25 and older. Patients aged 50 and older (N=1419) were more likely to be male
(P,0.0001) and located in rural areas (P=0.003) than those aged 25–49. Crude survival estimates among those aged 50–59
were not statistically different from those aged 25–49 (P=0.925). However, survival among those aged 60 and older
(N=345) was worse (P=0.019) than among those 25–59. In the proportional hazards model, after controlling for sex and
stage at initiation, survival in those aged 50–59 did not differ significantly from those aged 25–49 (hazard ratio 1.00 (95% CI:
0.79 to 1.27; P=0.998) but the hazard ratio was 1.46 (95% CI: 1.03 to 2.06; P=0.032) for those aged 60 and older compared
to those aged 25–49.
Conclusions: Treatment outcomes of those aged 50–59 are similar to those aged 25–49. A better understanding of how
older adults present for and respond to treatment is critical to improving HIV services.
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Introduction
There are approximately 3 million people aged 50 and older in
sub-Saharan Africa who are HIV-positive, representing more than
13% of all HIV cases in the region [1]. These figures are likely to
increase as the number of people on life-prolonging anti-retroviral
treatment (ART) grows. Despite this, older people have been
neglected in the global and regional HIV response. UNAIDS and
other prominent data sources report prevalence rates of those aged
15–49 [2] and few services directly target those aged 50 and older
[3,4].
The evidence base on ART presentation, initiation and
outcomes for older adults from developed countries has been
growing over the past few years [5,6]. There is evidence that older
adults are more likely to be late presenters with more AIDS-
defining diseases and are more likely to die before treatment
initiation [7–10]. After initiation of ART, studies have also shown
higher mortality [11] and slower immune system reconstitution
[12] leading some to suggest that older adults should initiate
treatment earlier than younger counterparts [13].
There has not however been much analysis conducted on older
adults in sub-Saharan Africa [14,15]. Recently, one Ugandan and
one South African study provided some of the first evidence
reporting on treatment outcomes revealing elderly age status (50
and older) associated with higher mortality [16,17].
A recent study revealed that older Africans are less likely to have
a good understanding of HIV, are less likely to have been tested
and are less likely to be aware of treatment availability [18]. Along
with this, for older adults in sub-Saharan Africa, issues of stigma,
lack of access to health services, poor overall health [19] and ageist
views on sexual behavior might negatively impact on the
effectiveness of ART scale-up efforts.
In Malawi, a country with a 2009 HIV prevalence of 11%
among those aged 15–49, analysis of 2007 UNAIDS data
suggested that there are approximately 156,000 people over 50
who are living with HIV in Malawi or 16.8% of the total [1].
Furthermore, people over 50 make up 9.3% of Malawi’s
population [20]. ART coverage has expanded dramatically over
the past fewyearsand,as of 2009,72% ofthosewho needed treatment
were receiving it based on 2006 World Health Organization ART
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increase. Despite this, no published work exists for Malawi
specifically examining HIV among older adults.
Using data from Zomba District in Malawi, this study examines
the characteristics of older adults on ART, their condition at
initiation and their treatment outcomes compared against younger
adults.
Methods
Subjects were adults aged 25 and older at time of ART
initiation residing in Zomba District in southern Malawi who
accessed ART services in the district’s 23 health facilities between
1 July 2005 and 30 June 2010.
The methods used in this study have been described in detail
elsewhere (Chan et al 2010) [21]. In brief, a retrospective cohort
analysis was performed using data collected with standard Malawi
Ministry of Health (MOH) ART monitoring tools. ART provision
was implemented as per MOH guidelines based on WHO clinical
staging or CD4 count ,250 cells ?mm3 where measurement of
CD4 is available. The first line ART regimen in Malawi is
stavudine, lamivudine and nevirapine in fixed-dosed combination.
After initiation, follow-up was monthly and then, after approxi-
mately 6 months, patients were followed less often depending on
assessment of adherence. In the project district, mortality was
documented by trained health workers in health facilities and by
reports from trained patient guardians where deaths occurred at
home. Defaulter tracing was also conducted which revealed
additional deaths.
Analyses in this paper only included those aged 25 and older to
exclude those regarded by MDG [22] and UNGASS [23]
indicators as adolescents. Age was defined as age at treatment
initiation. The 23 health facilities where MOH ART provision is
supported by Dignitas International were classified as urban, semi-
urban or rural based on location and catchment area of facility.
Analysis of conditions at initiation was based on examination at
baseline of 52 HIV-related conditions detailed in WHO clinical
staging including: acute ulcerative mouth infections, Kaposi’s
sarcoma, various types of pneumonia and weight loss to name a
few. As per Malawi MOH guidelines, individuals were initiated
based on characterization as being in WHO clinical stage 3 or 4
or, if characterized as Stage 1 or 2, based on low CD4 count if
available. As a result, baseline CD4 counts were collected for only
47% of patients. Additionally, CD4 testing capacity was only
available in urban settings with blood samples from rural patients
being sent to urban facilities as needed.
Statistical analyses included Chi-square tests for categorical
variables and t-tests for continuous variables to compare differences
between groups. Logistic regression analyses were used for
categorical outcomes including WHO clinical stage and number
of conditions at initiation. Interactions between age and sex and
between age and location of initiation were tested in the logistic
regression analyses. Cox proportional hazard regression models
were used to evaluate relationships between age, sex and status at
initiation and treatment outcomes (death). CD4 count was not used
for these analyses due to high number of missing values. Differences
in survival time between groups of subjects by age categories and by
sex were investigated using Kaplan–Meier survival plots. Data
analysis was performed using SAS v.9.2.
For the Cox proportional hazards model and Kaplan-Meier
survival curves, analyses excluded those whose follow-up status
was characterized in the dataset as ‘‘missing’’ or suspected of
having ‘‘defaulted.’’ This represented 22.7% (N=2475) of all
those aged 25 and older who had initiated in the five year period
from 1 July 2005 to 30 June 2010. Based on a systematic review
[24] and data from two studies in Malawi, [25,26] we estimate that
approximately 41–50% of those lost to follow-up would have died
within approximately two years. Analyses were run to identify
differences in characteristics between those in the analyzed cohort
versus those excluded.
Ethics Statement
The study analysis received approval from the National Health
Sciences Research Committee of Malawi in April 2011.
Results
There were 10888 patients aged 25 and older who had initiated
ART between 1 July 2005 and 30 June 2010 in the database. Of
those, 6789 (62.4%) were female; 9469 (87.0%) were aged 25–49,
1074 (9.9%) were 50–59 and 345 (3.2%) were aged 60 and older.
The older age groups had significantly (P,0.0001) higher per-
centages of male patients than the younger age groups: 44.9% of
those 50 years and older were male compared to 36.6% of those
aged under 50 years (table 1). Older adults were also more likely to
be living in a rural location compared to younger adults (P=0.003).
There wereno significant differencesbetween age groups for year of
initiation or TB status at baseline.
After adjusting for location and sex, age group was not
associated with WHO clinical stage at initiation of ART or with
the number of HIV-related conditions at initiation. Females were
slightly more likely than males to have two or more HIV-related
conditions at initiation (odds ratio (OR): 1.17 (95% confidence
interval (CI): 1.05 to 1.32)). Those who initiated in semi-urban and
rural areas were less likely (OR: 0.61 (95% CI: 0.53 to 0.69)) to
have two or more conditions compared to urban patients.
Interactions between age and location and between age and sex
were tested and were not significant.
Data were available for 8412 individuals for the analysis of
treatment outcomes. Of these, 765 (9.1%) died within 5 years of
initiation of treatment. Survival rates among those aged 50–59
were not statistically different from those aged 25–49 (P=0.92)
(figure 1). Survival among those aged 60 and older was
significantly worse (P=0.02) than among those 25–59. Those
aged 60 and older also had significantly worse survival (P=0.04)
than those aged 50–59. Further analysis revealed that sex was a
significant predictor of survival (P,0.0001), with males having
worse survival than females (figure 2).
After controlling for sex and WHO clinical stage at initiation,
the hazard ratio (HR) for those aged 50–59 compared to those
aged 25–49 was 1.00 (95% CI: 0.79 to 1.27; P=0.99) (table 2).
Compared to those aged 25–49 years, those aged 60 and older
were at significant increased risk of dying (HR=1.46 (95% CI:
1.03 to 2.06; P=0.03)). Controlling for stage and age group, being
female reduced the risk of death with a hazard ratio of 0.58 (95%
CI: 0.50 to 0.67; P,0.0001). As expected, WHO clinical stage was
strongly associated with mortality. After controlling for sex and age
group, compared to Stage 1, the hazard ratio for Stage 3 was 5.4
(95% CI: 1.74 to 16.94) and the hazard ratio for Stage 4 was 12.3
(95% CI: 3.93 to 38.32).
Of the 765 who died, 629 (82.2%) died within the first year of
ART initiation. The pattern of mortality between the age groups
was unchanged with those 50–59 have similar mortality to those
aged 25–49 with those 60 and older having higher mortality.
Due to missing outcome data, 2475 (22.7%) of subjects were
excluded from survival analyses. The mean age and baseline CD4
of those included in analysis were not meaningfully different from
the mean age of those excluded but those excluded were more
ART among Older Adults in Zomba, Malawi
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as WHO Stage 4 on initiation of treatment (table 3). Importantly,
the relative differences in sex and WHO Stage between those
included and those excluded from survival analyses were largely
consistent among those over 50 and among those under 50.
If the excluded patients are included in the survival analysis up
to the point when they were classified as missing, the results and
significance noted above remained in the same direction and
changed only slightly in magnitude. The hazard ratio for those
aged 60 and older became 1.52 (95% CI: 1.08 to 2.15; P=0.0168)
while the hazard ratio for those aged 50–59 remained 1.00
compared to those aged 25–49. Using the Kaplan-Meier survival
curves, when including those with incomplete outcome data, those
60 and older had significantly worse survival than those 50–59
(P=0.03).
Discussion
Adults aged 50 and older in Zomba District, Malawi, who
initiated ART were more likely than younger adults to be male
and be receiving treatment at a rural health facility. However,
based on WHO clinical stage and number of HIV-related
conditions at ART initiation, older adults in this population were
no sicker at presentation than younger adults.
We found no difference in mortality on treatment among those
aged 50 to 59 years compared to those aged 25 to 49, indicating
that people in their fifties respond just as well to treatment as
younger people. Survival among those aged 60 and older was
reduced; however, this is to be expected due to higher rates of all-
cause mortality among older adults. In this study, sex was a much
better predictor of survival than age in the Zomba District ART
cohort. This study suggests that females are more likely to survive
than men.
In our study, 9% of those initiated on treatment died over the
course of the five years. This level of mortality was higher than was
found in Uganda [16] but comparable to data seen in South
Africa, Cote d’Ivoire and elsewhere in Malawi [15].
The lack of significant differences in the clinical condition of
older adults at initiation of ART is contrary to what has been
hypothesized. In Brazil, those aged 60 and older had more AIDS-
Table 1. Characteristics of patients at initiation of antiretroviral therapy.
25–49 50–59 60+
N% N% N %
P Value
(25–49 vs 50+)
Sex
Female 6007 63.4% 613 57.1% 169 49.0% ,0.0001
Male 3462 36.6% 461 42.9% 176 51.0%
WHO Stage / Reason for ART Initiation
Stage 1 341 3.6% 29 2.7% 10 2.9% 0.188
Stage 2 3300 34.9% 363 33.9% 121 35.4%
Stage 3 4281 45.3% 511 47.8% 177 51.8%
Stage 4 1530 16.2% 167 15.6% 34 9.9%
Missing
a 17 0.2% 3 0.3% 3 0.9%
ART Location
Urban 4971 52.5% 525 48.9% 154 44.6% 0.003
Semi Urban 1600 16.9% 177 16.5% 71 20.6%
Rural 2898 30.6% 372 34.6% 120 34.8%
CD4 cell counts at baseline (cells/ml)
less than or equal to 50 608 13.7% 39 7.7% 10 5.9% 0.001
between 50 and 99 748 16.8% 87 17.2% 28 16.6%
between 100 and 199 1515 34.0% 179 35.4% 55 32.5%
between 200 and 299 1388 31.2% 184 36.4% 68 40.2%
300 or over 192 4.3% 17 3.4% 8 4.7%
Missing
a 5018 53.0% 569 52.9% 176 51.0%
Median baseline CD4 157 171 185
Tuberculosis status at baseline
TB past or present 1406 14.8% 155 14.4% 52 15.1% 0.797
No TB 8063 85.2% 919 85.6% 293 84.9%
Year of ART Initiation
2009–2010 3827 40.4% 415 38.6% 150 43.5% 0.287
2007–2008 4354 46.0% 525 48.9% 154 44.6%
2005–2006 1287 13.6% 134 12.5% 41 11.9%
aMissing values not included in percentages in categories above.
Zomba District by age category 25–49,50–59 and 60 and older who initiated treatment from July 2005 to June 2010.
doi:10.1371/journal.pone.0026546.t001
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PLoS ONE | www.plosone.org 3 October 2011 | Volume 6 | Issue 10 | e26546Figure 1. Survival estimates by age. Kaplan-Meier survival estimates by age group for those aged 25 and older who initiated treatment in Zomba
District between 1 July 2005 and 30 June 2010. Blue is 25–49 (N=7297); Red is 50–59 (N=839); Green is 60+ (N=276).
doi:10.1371/journal.pone.0026546.g001
Figure 2. Survival estimates by sex. Kaplan-Meier survival estimates by sex for those aged 25 and older who initiated treatment in Zomba District
between 1 July 2005 and 30 June 2010. Blue is Male (N=3057); Red is Female (N=5355).
doi:10.1371/journal.pone.0026546.g002
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review of developed country studies found that older adults
presented later and sicker [6]. However, the recent South African
ART among older adults study found that they did not present
with more advanced disease than younger individuals [17]. Similar
to our findings, the Ugandan study by Bakanda and colleagues
also found that older adults were more likely to be male and did
not differ in WHO clinical stage at treatment initiation [16].
With regard to treatment outcomes, the Ugandan study found
that being aged 50 and older was associated with mortality
compared to those 18 to 49 after controlling for other variables
[16]. The South African study found that older adults had 32%
excess mortality compared to those 25 to 49 [17]. A four site cross-
Africa study found that treatment outcomes for over 50s were
worse than for younger age groups [15]. Ours is the first study that
breaks down the over 50 group into additional age categories for
analysis.
Especially for the 50–59 age group, our data confirms what has
been seen in non-African studies where older HIV-infected
patients responded as well to ART as younger age groups [27–
30]. A Brazilian study that compared those aged 20–39 against
those aged 60 and older found that, once on ART, mortality
between the two groups was similar [8]. A recent case-control
study, in which the outcome in patients aged 55 years or older was
compared with patients aged 35 years or younger, all treated with
ART, concluded that the virological outcome did not differ
between groups [31]. The picture is complex however as a number
of other studies have found that there is slower recovery of CD4
levels among older adults [12,32]. The eventual higher mortality
among older adults in the study was expected and has been seen in
other studies [33,34].
Our finding that women on ART are more likely to survive than
men has been observed in other studies in Malawi [35] and across
Africa [36]. Potential reasons for this sex difference could be that
men seek care at a more advanced stage of illness and have poorer
levels of adherence.
The strength of the study is its inclusion of program data from
an entire district’s ART population including urban and rural
sites. However, study limitations include concerns regarding
accuracy and consistency that are associated with use of
operational data. Because data were extracted from routine
monitoring and evaluation indicators, information that might be
included in a prospective study is not available, as it is not a part of
routine clinical care for ART provision under the Malawi MOH
Table 2. Cox proportional hazards models for mortality.
Model with age, sex and WHO Stage at initiation (N=8390) Model with Age and Sex (N=8412)
Variable Hazard ratio 95% confidence limits P Value Hazard ratio 95% confidence limits P Value
Age group 0.098 0.216
25–49 1.00 1.00
50–59 1.00 0.79–1.27 0.998 0.97 0.77–1.23 0.826
60+ 1.46 1.03–2.06 0.032 1.35 0.96–1.91 0.086
Sex 0.58 0.50–0.67 ,0.0001 0.52 0.46–0.60 ,0.0001
WHO Stage ,0.0001
Stage 1 1.00
Stage 2 2.38 0.76–7.49 0.139
Stage 3 5.43 1.74–16.94 0.004
Stage 4 12.27 3.93–38.32 ,0.0001
doi:10.1371/journal.pone.0026546.t002
Table 3. Comparison of those included in survival analysis and those excluded.
Included in Analysis (N) Excluded from Analysis (N)
Total population Age (mean) 38.3 (8412) 38.0 (2475)
Sex (% male) 36.3% (3057) 42.1% (1042)
WHO Stage 3 and 4 (%) 61.1% (5122) 63.8 (1578)
Baseline CD4 (mean) 162.6 (4055) 154.6 (1070)
25 to 49 Age (mean) 35.5 (7297) 35.5 (2171)
Sex (% male) 35.2% (2569) 41.1% (893)
WHO Stage 3 and 4 (%) 60.8% (4425) 63.9% (1386)
50 and older Age (mean) 56.1 (1115) 56.0 (304)
Sex (% male) 43.8% (488) 49.0% (149)
WHO Stage 3 and 4 (%) 62.9% (697) 63.2% (192)
doi:10.1371/journal.pone.0026546.t003
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setting. Specifically, high levels of missing baseline CD4 data made
usage of that variable difficult.
A further limitation was the approximately 20% loss to follow
up in the dataset. However, the levels of loss to follow-up in this
study are comparable to those seen in a review of loss to follow-up
across Africa [24]. The exclusion of those lost to follow-up from
analysis is likely to have led to underestimation of the absolute
number of deaths and mortality rates. However, because the
magnitude of differences in characteristics of those included and
excluded was similar in the different age groups, the relative risk of
death (or hazard ratio) comparing those aged 50 years and over
with those aged under 50 was unlikely to be biased.
While some studies have also excluded those lost to follow-up,
[15] other studies have used randomization techniques to impute
outcome status [16,37]. These imputation techniques make
assumptions about which variables are correlated with mortality.
For example, Bakanda and colleagues [16] assumed that those
with lower CD4 count and those who were older were more likely
to die. We did not conduct outcome imputation for those lost to
follow-up. Given that age and its relation to mortality was the
primary outcome of this study, it was felt that including age in the
imputation method would be inappropriate as the method of
imputation would be directly related to the primary outcome of
interest. Baseline CD4 was also not ideal for use as an imputation
variable due to the large number of non-random missing values in
our dataset. In the future, greater efforts will be needed to trace
those lost to follow-up and examine specific characteristics and
determinants of mortality [38,39].
That older adults respond well to ART despite a lack of
specifically targeted services is an encouraging sign for ART scale-
up. This evidence can be used to combat ageist stigma [40] and to
encourage promotion of services among this age group. There
have been suggestions there might be higher adherence rates
among the elderly – which has been found in developed countries
[27,41] – which may be driving the positive treatment response.
With the ageing of the epidemic, HIV has become a complex
chronic disease characterised by increasing rates of co-morbid
conditions including liver and renal disease, cancers, osteoporosis,
neurocognitive and cardiovascular diseases [5]. It is well known
that older people’s immune systems weaken with age regardless of
HIV status leaving older people at greater susceptibility to a range
of conditions [42,43] – but this has not been specifically studied in
Africa among those on ART. The ageing of the epidemic has
implications on service delivery with a growing need for integrated
diagnostic and treatment services for HIV and non-communicable
diseases.
Older adults have been largely neglected by the global HIV
response but there are encouraging signs that those aged 50 and
older are starting to be seen by the HIV community as productive,
fully active contributors, care givers, and educators, whose
susceptibility to HIV needs to be integrated into the core of the
response to the epidemic.
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